EDITAS MEDICINE, INC. Operating Cash Flow
EDITAS MEDICINE, INC. (EDIT) reported Operating Cash Flow of -$52.63 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Operating Activities
us-gaap:NetCashProvidedByUsedInOperatingActivities · last filed 2026-08-05
- EDITAS MEDICINE, INC. net cash provided by (used in) operating activities for the quarter ending 2026-06-30 was -$29.57M.
- EDITAS MEDICINE, INC. net cash provided by (used in) operating activities for the quarter ending 2026-03-31 was -$23.06M.
- EDITAS MEDICINE, INC. net cash provided by (used in) operating activities for the quarter ending 2025-12-31 was -$36.39M.
- EDITAS MEDICINE, INC. net cash provided by (used in) operating activities for the quarter ending 2025-09-30 was -$30.84M.
- EDITAS MEDICINE, INC. net cash provided by (used in) operating activities for fiscal 2025 was -$165.24M.
- EDITAS MEDICINE, INC. net cash provided by (used in) operating activities for fiscal 2024 was -$210.28M.
- EDITAS MEDICINE, INC. net cash provided by (used in) operating activities for fiscal 2023 was -$132.18M.
- EDITAS MEDICINE, INC. net cash provided by (used in) operating activities for fiscal 2022 was -$177.35M.
| Period end | Net Cash Provided by (Used in) Operating Activities 3 month | Net Cash Provided by (Used in) Operating Activities 6 month | Net Cash Provided by (Used in) Operating Activities 9 month | Net Cash Provided by (Used in) Operating Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$29.57M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | -$52.63M 10-Q · filed 2026-08-05 | -$89.02M derived: sum of 3 quarters · filed 2026-08-05 | -$119.86M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | -$23.06M 10-Q · filed 2026-05-05 | -$59.45M derived: sum of 2 quarters · filed 2026-05-05 | -$90.29M derived: sum of 3 quarters · filed 2026-05-05 | -$140.50M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | -$36.39M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | -$67.23M derived: sum of 2 quarters · filed 2026-03-09 | -$117.44M derived: sum of 3 quarters · filed 2026-08-05 | -$165.24M 10-K · filed 2026-03-09 |
| 2025-09-30 | -$30.84M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | -$81.06M derived: sum of 2 quarters · filed 2026-08-05 | -$128.85M 10-Q · filed 2025-11-10 | -$179.62M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | -$50.21M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | -$98.01M 10-Q · filed 2026-08-05 | -$148.77M derived: sum of 3 quarters · filed 2026-08-05 | -$201.36M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | -$47.80M 10-Q · filed 2026-05-05 | -$98.56M derived: sum of 2 quarters · filed 2026-05-05 | -$151.15M derived: sum of 3 quarters · filed 2026-05-05 | -$208.21M derived: sum of 4 quarters · filed 2026-05-05 |
| 2024-12-31 | -$50.76M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | -$103.35M derived: sum of 2 quarters · filed 2026-03-09 | -$160.41M derived: sum of 3 quarters · filed 2026-03-09 | -$210.28M 10-K · filed 2026-03-09 |
| 2024-09-30 | -$52.59M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | -$109.65M derived: sum of 2 quarters · filed 2025-11-10 | -$159.52M 10-Q · filed 2025-11-10 | -$181.76M derived: sum of 4 quarters · filed 2025-11-10 |
| 2024-06-30 | -$57.06M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | -$106.93M 10-Q · filed 2025-08-12 | -$129.17M derived: sum of 3 quarters · filed 2025-08-12 | -$164.63M derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | -$49.87M 10-Q · filed 2025-05-12 | -$72.11M derived: sum of 2 quarters · filed 2025-05-12 | -$107.57M derived: sum of 3 quarters · filed 2025-05-12 | -$146.28M derived: sum of 4 quarters · filed 2025-05-12 |
| 2023-12-31 | -$22.24M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-05 | -$57.70M derived: sum of 2 quarters · filed 2025-03-05 | -$96.41M derived: sum of 3 quarters · filed 2025-03-05 | -$132.18M 10-K · filed 2025-03-05 |
| 2023-09-30 | -$35.46M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-04 | -$74.17M derived: sum of 2 quarters · filed 2024-11-04 | -$109.94M 10-Q · filed 2024-11-04 | -$152.21M derived: sum of 4 quarters · filed 2025-03-05 |
| 2023-06-30 | -$38.71M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-07 | -$74.48M 10-Q · filed 2024-08-07 | -$116.75M derived: sum of 3 quarters · filed 2025-03-05 | -$164.76M derived: sum of 4 quarters · filed 2025-03-05 |
| 2023-03-31 | -$35.77M 10-Q · filed 2024-05-08 | -$78.04M derived: sum of 2 quarters · filed 2025-03-05 | -$126.05M derived: sum of 3 quarters · filed 2025-03-05 | -$163.89M derived: sum of 4 quarters · filed 2025-03-05 |
| 2022-12-31 | -$42.27M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-05 | -$90.28M derived: sum of 2 quarters · filed 2025-03-05 | -$128.12M derived: sum of 3 quarters · filed 2025-03-05 | -$177.35M 10-K · filed 2025-03-05 |
| 2022-09-30 | -$48.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-03 | -$85.85M derived: sum of 2 quarters · filed 2023-11-03 | -$135.08M 10-Q · filed 2023-11-03 | -$169.66M derived: sum of 4 quarters · filed 2024-02-28 |
| 2022-06-30 | -$37.84M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-02 | -$87.07M 10-Q · filed 2023-08-02 | -$121.65M derived: sum of 3 quarters · filed 2024-02-28 | -$162.44M derived: sum of 4 quarters · filed 2024-02-28 |
| 2022-03-31 | -$49.23M 10-Q · filed 2023-05-05 | -$83.81M derived: sum of 2 quarters · filed 2024-02-28 | -$124.59M derived: sum of 3 quarters · filed 2024-02-28 | -$163.55M derived: sum of 4 quarters · filed 2024-02-28 |
| 2021-12-31 | -$34.58M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28 | -$75.37M derived: sum of 2 quarters · filed 2024-02-28 | -$114.32M derived: sum of 3 quarters · filed 2024-02-28 | -$163.80M 10-K · filed 2024-02-28 |
| 2021-09-30 | -$40.78M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-02 | -$79.74M derived: sum of 2 quarters · filed 2022-11-02 | -$129.22M 10-Q · filed 2022-11-02 | -$169.32M derived: sum of 4 quarters · filed 2023-02-22 |
| 2021-06-30 | -$38.96M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-03 | -$88.44M 10-Q · filed 2022-08-03 | -$128.54M derived: sum of 3 quarters · filed 2023-02-22 | -$183.34M derived: sum of 4 quarters · filed 2023-02-22 |
| 2021-03-31 | -$49.48M 10-Q · filed 2022-05-04 | -$89.58M derived: sum of 2 quarters · filed 2023-02-22 | -$144.38M derived: sum of 3 quarters · filed 2023-02-22 | -$175.24M derived: sum of 4 quarters · filed 2023-02-22 |
| 2020-12-31 | -$40.10M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-22 | -$94.90M derived: sum of 2 quarters · filed 2023-02-22 | -$125.76M derived: sum of 3 quarters · filed 2023-02-22 | -$179.84M 10-K · filed 2023-02-22 |
| 2020-09-30 | -$54.80M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-09 | -$85.66M derived: sum of 2 quarters · filed 2021-11-09 | -$139.74M 10-Q · filed 2021-11-09 | -$98.72M derived: sum of 4 quarters · filed 2022-02-24 |
| 2020-06-30 | -$30.86M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05 | -$84.94M 10-Q · filed 2021-08-05 | -$43.92M derived: sum of 3 quarters · filed 2022-02-24 | -$70.80M derived: sum of 4 quarters · filed 2022-02-24 |
| 2020-03-31 | -$54.09M 10-Q · filed 2021-05-06 | -$13.06M derived: sum of 2 quarters · filed 2022-02-24 | -$39.95M derived: sum of 3 quarters · filed 2022-02-24 | -$65.75M derived: sum of 4 quarters · filed 2022-02-24 |
| 2019-12-31 | $41.02M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-24 | $14.14M derived: sum of 2 quarters · filed 2022-02-24 | -$11.67M derived: sum of 3 quarters · filed 2022-02-24 | -$40.67M 10-K · filed 2022-02-24 |
| 2019-09-30 | -$26.88M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-06 | -$52.69M derived: sum of 2 quarters · filed 2020-11-06 | -$81.69M 10-Q · filed 2020-11-06 | -$80.37M derived: sum of 4 quarters · filed 2021-02-26 |
| 2019-06-30 | -$25.81M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-07 | -$54.81M 10-Q · filed 2020-08-07 | -$53.48M derived: sum of 3 quarters · filed 2021-02-26 | -$61.32M derived: sum of 4 quarters · filed 2021-02-26 |
| 2019-03-31 | -$29.00M 10-Q · filed 2020-05-08 | -$27.68M derived: sum of 2 quarters · filed 2021-02-26 | -$35.52M derived: sum of 3 quarters · filed 2021-02-26 | -$52.25M derived: sum of 4 quarters · filed 2021-02-26 |
| 2018-12-31 | $1.33M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-26 | -$6.51M derived: sum of 2 quarters · filed 2021-02-26 | -$23.25M derived: sum of 3 quarters · filed 2021-02-26 | -$45.71M 10-K · filed 2021-02-26 |
| 2018-09-30 | -$7.84M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-12 | -$24.57M derived: sum of 2 quarters · filed 2019-11-12 | -$47.03M 10-Q · filed 2019-11-12 | -$72.10M derived: sum of 4 quarters · filed 2020-02-26 |
| 2018-06-30 | -$16.73M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-07 | -$39.19M 10-Q · filed 2019-08-07 | -$64.26M derived: sum of 3 quarters · filed 2020-02-26 | -$92.24M derived: sum of 4 quarters · filed 2020-02-26 |
| 2018-03-31 | -$22.46M 10-Q · filed 2019-05-08 | -$47.53M derived: sum of 2 quarters · filed 2020-02-26 | -$75.51M derived: sum of 3 quarters · filed 2020-02-26 | -$101.67M derived: sum of 4 quarters · filed 2020-02-26 |
| 2017-12-31 | -$25.07M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-26 | -$53.05M derived: sum of 2 quarters · filed 2020-02-26 | -$79.21M derived: sum of 3 quarters · filed 2020-02-26 | -$9.42M 10-K · filed 2020-02-26 |
| 2017-09-30 | -$27.98M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-08 | -$54.14M derived: sum of 2 quarters · filed 2018-11-08 | $15.65M 10-Q · filed 2018-11-08 | $1.98M derived: sum of 4 quarters · filed 2019-03-01 |
| 2017-06-30 | -$26.16M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-07 | $43.63M 10-Q · filed 2018-08-07 | $29.95M derived: sum of 3 quarters · filed 2019-03-01 | $12.91M derived: sum of 4 quarters · filed 2019-03-01 |
| 2017-03-31 | $69.79M 10-Q · filed 2018-05-04 | $56.11M derived: sum of 2 quarters · filed 2019-03-01 | $39.07M derived: sum of 3 quarters · filed 2019-03-01 | |
| 2016-12-31 | -$13.68M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-01 | -$30.72M derived: sum of 2 quarters · filed 2019-03-01 | -$50.25M 10-K · filed 2019-03-01 | |
| 2016-09-30 | -$17.04M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-08 | -$36.57M 10-Q · filed 2017-11-08 | ||
| 2016-06-30 | -$19.53M 10-Q · filed 2017-08-09 | |||
| 2015-12-31 | -$5.44M 10-K · filed 2018-03-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |